BIOMAT Database Logo BIOMAT Database Logo

[A randomized trial comparing ACF (adriamycin, cyclophosphamide, ftorafur) and ACF/MVMF (mitomycin C, vincristine, methotrexate, ftorafur)--a non-cross-resistant alternating chemotherapy of recurrent and advanced breast cancer]. 1989

T Mukaiyama, and M Ogawa, and N Horikoshi, and K Inoue, and A Tada, and K Ueno, and H Yamazaki, and T Nakamura, and Y Ito, and J Inagaki
Dept. of Clinical Oncology, Cancer Institute Hospital.

Of 47 consecutive patients with advanced breast cancer, we randomly assigned 24 to receive Arm A; ACF alone (Adriamycin, Cyclophosphamide, Ftorafur) and 23 to receive Arm B; 2 cycles of ACF alternating one cycle of MVMF (Mitomycin C, Vincristine, Methotrexate, Ftorafur--a combination of drugs not cross-resistant with ACF). The response rate was 66% in Arm A and 52% in Arm B. The median duration of response was significantly longer in Arm B (11 months in Arm A, 28.8 months in Arm B) due to prolongation of duration to administer adriamycin in Arm B. But the median survival time was 30.7 months in Arm A and 24.5 months in Arm B, and significantly longer in Arm A until 10 months. These results were due to the difference in response rate during induction therapy (58% in Arm A, 26% in Arm B) reflected in the dose intensity of Adriamycin (13 mg/m2/w in Arm A, 6.7 mg/m2/w in Arm B) and the higher CR rate in Arm A, because CR cases had a significantly longer survival than PR and NC cases in both arms. We suppose that achieving CR by an intensive regimen containing adriamycin and adopting a non-cross-resistant regimen can help prolong survival in advanced breast cancer.

UI MeSH Term Description Entries
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008937 Mitomycins A group of methylazirinopyrroloindolediones obtained from certain Streptomyces strains. They are very toxic antibiotics used as ANTINEOPLASTIC AGENTS in some solid tumors. PORFIROMYCIN and MITOMYCIN are the most useful members of the group.
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D005260 Female Females

Related Publications

T Mukaiyama, and M Ogawa, and N Horikoshi, and K Inoue, and A Tada, and K Ueno, and H Yamazaki, and T Nakamura, and Y Ito, and J Inagaki
[A randomized trial of adriamycin, cyclophosphamide, ftorafur (ACF) and adriamycin, cyclophosphamide, ftorafur, methotrexate (ACFM) in patients with advanced breast cancer].
September 1984, Gan to kagaku ryoho. Cancer & chemotherapy,
T Mukaiyama, and M Ogawa, and N Horikoshi, and K Inoue, and A Tada, and K Ueno, and H Yamazaki, and T Nakamura, and Y Ito, and J Inagaki
A randomized trial of adriamycin, cyclophosphamide, ftorafur (ACF) and adriamycin, cyclophosphamide, ftorafur, methotrexate (ACFM) in patients with advanced breast cancer.
January 1984, Cancer chemotherapy and pharmacology,
T Mukaiyama, and M Ogawa, and N Horikoshi, and K Inoue, and A Tada, and K Ueno, and H Yamazaki, and T Nakamura, and Y Ito, and J Inagaki
A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer.
August 1991, British journal of cancer,
T Mukaiyama, and M Ogawa, and N Horikoshi, and K Inoue, and A Tada, and K Ueno, and H Yamazaki, and T Nakamura, and Y Ito, and J Inagaki
Chemotherapy of advanced breast cancer: a randomized trial of vincristine, Adriamycin, and cyclophosphamide (VAC) versus cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP).
October 1981, Cancer,
T Mukaiyama, and M Ogawa, and N Horikoshi, and K Inoue, and A Tada, and K Ueno, and H Yamazaki, and T Nakamura, and Y Ito, and J Inagaki
[CMF (cyclophosphamide, methotrexate, ftorafur) chemotherapy in advanced breast cancer].
January 1983, Orvosi hetilap,
T Mukaiyama, and M Ogawa, and N Horikoshi, and K Inoue, and A Tada, and K Ueno, and H Yamazaki, and T Nakamura, and Y Ito, and J Inagaki
[Combination chemotherapy of advanced gastric cancer with adriamycin, mitomycin C, and ftorafur].
April 1983, Gan to kagaku ryoho. Cancer & chemotherapy,
T Mukaiyama, and M Ogawa, and N Horikoshi, and K Inoue, and A Tada, and K Ueno, and H Yamazaki, and T Nakamura, and Y Ito, and J Inagaki
Cyclophosphamide, methotrexate,5-fluorouracil, alternating with adriamycin and mitomycin C in metastatic breast cancer: a pilot study.
June 1987, Tumori,
T Mukaiyama, and M Ogawa, and N Horikoshi, and K Inoue, and A Tada, and K Ueno, and H Yamazaki, and T Nakamura, and Y Ito, and J Inagaki
[Combination chemotherapy with mitomycin C, methotrexate, and vincristine (MMV) for metastatic breast cancer refractory to adriamycin].
March 1983, Gan to kagaku ryoho. Cancer & chemotherapy,
T Mukaiyama, and M Ogawa, and N Horikoshi, and K Inoue, and A Tada, and K Ueno, and H Yamazaki, and T Nakamura, and Y Ito, and J Inagaki
[A case of adriamycin and methotrexate-resistant recurrent breast cancer treated with doxifluridine and mitomycin C].
August 1999, Gan to kagaku ryoho. Cancer & chemotherapy,
T Mukaiyama, and M Ogawa, and N Horikoshi, and K Inoue, and A Tada, and K Ueno, and H Yamazaki, and T Nakamura, and Y Ito, and J Inagaki
Combination chemotherapy for advanced breast cancer utilizing vincristine, adriamycin, and cyclophosphamide (VAC).
January 1979, Cancer,
Copied contents to your clipboard!